abstract |
The present invention relates to the combination of at least one agent and a reduced calorie intake for use in the treatment of a blood cancer. In particular the agent is a CD20 inhibitor Bruton's tyrosine kinase inhibitor, a phosphoinositide 3-kinase inhibitor, a class I and/class II histone deacetylase inhibitor, a non-taxane replication inhibitor or a proteasome inhibitor. The combination is advantageous in that it sensitize cancer cells to said agent while it protects normal cells from toxicity induced by said agent. |